Future Directions in Graft Versus Host Disease
Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.
Discussion of Long-Term Effects of GVHD Therapy
Chronic GVHD specialists share commentary on long-term effects of graft versus host disease and therapies for the condition.
Summary of Axatilimab for cGVHD
The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.
Real-World Experience with Belumosudil
Clinical experiences with belusmosudil are shared among the panel.
The ROCKstar Study of Belumosudil in cGVHD
Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.
The REACH3 Clinical Trial of Ruxolitinib in Chronic GVHD
Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.
The iNTEGRATE Trial: Ibrutinib With Prednisone as First-Line Therapy for cGVHD
The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.
Ibrutinib as Second-Line Therapy for Steroid-Refractory Chronic GVHD
Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.
Therapy Options for Steroid-Refractory Chronic GVHD
Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.
Steroid-Refractory Chronic GVHD Background
The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.
Treatment Goals for a Patient With Chronic GVHD
The group discusses treatment goals and patient education for chronic GVHD.
Patient Case: A 48-Year-Old Man with Chronic GVHD
Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.
The Chronic GVHD Treatment Paradigm
Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.
The NIH Clinical Scoring of Organ Systems
Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.
Assessment of Chronic GVHD Symptoms
Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.
The Role of Acupuncture Prior to BCG Treatment in NMIBC
Discussing findings from a phase 1/2 study, Sarah P. Psutka MD, looks at the use of acupuncture for patients with non muscle-invasive bladder cancer prior to induction of their BCG treatment.
Identification of Patients at High Risk for GVHD
The panelists share their insights on the identification of patients at high risk for GVHD.
Statistics on the Incidence of Chronic GVHD
Dr Chen presents statistics on the incidence of chronic graft versus host disease.
Signs and Symptoms of Acute and Chronic GVHD
Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.
Current GVHD Prophylaxis Strategies
Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.
Overview of GVHD Risk Factors
Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.
Graft versus Host Disease Background
A panel of experts discusses the types of graft versus host disease and the biologic pathways that are thought to be involved.
Identifying Post CAR-T Issues in Community Oncology Patients
Mazyar Shadman, MD, MPH, explains how community oncologists can care for their patient after they have been treated with chimeric antigen receptor T cells.
MB-106 Treatment Appears Safe and Effective in R/R B-Cell Malignancies
Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Phase 1/2 Study Examines MB-106 in Various Positive B-cell Malignancies
Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.
Investigation of Novel CAR T Product, MB-106, in Various R/R B-Cell Malignancies
In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Investigating CD20 CAR T-Cell Therapy in R/R CLL and Other B-NHL Histologies
Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.
Success of Nivolumab Plus Ipilimumab in Advanced RCC Carries Over to Non-Clear Cell Histology
Showing similarity to results from CheckMate 214, findings from CheckMate 920 shows that nivolumab plus ipilimumab can safety be administered to patients with non-clear cell renal cell carcinoma.
Newly-Approved Ide-Cel Becomes Available for Treatment at SCCA
Idecabtagene vicleucel is now an available treatment option for some patients with relapsed or refractory multiple myeloma who are being treated at Seattle Cancer Care Alliance.
2 Clarke Drive Cranbury, NJ 08512